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For many years there has been no substantial improvement in
survival of children with advanced neuroblastoma (NB) >1 year of
age (Matthay et al, 1996), despite the increasingly aggressive
therapies employed. To date, the most common treatment for such
patients comprises induction chemotherapy over a period of
several months, usually followed by high-dose consolidation
chemotherapy with the aim of destroying eventual residual tumour
cells resistant to induction chemotherapy. A better therapeutic
approach could be the development of intensive, multiple drug,
multiple modality therapy protocols at diagnosis in order to
rapidly destroy drug-resistant clones present ab initio and prevent
emergence of drug-resistant mutants. 
131-I-metaiodobenzylguanidine (131-I-MIBG), a radio-iodinated
aralkylguanidine, is a derivative of the neuron-blocking agent
guanethidine, which is capable of competing with norepinephrine
for an active uptake into neuroadrenergic tissue and derived
tumours (Wieland et al, 1980; Ivarone et al, 1993). Originally
employed for phaeochromocytoma imaging, 131-I-MIBG was
subsequently used for NB (Geatti et al, 1985). Owing to its
concentration in NB lesions, 131-I-MIBG has the potential for
specifically delivering very large radiation doses to NB malignant
cells, and NB is known to be a radio-sensitive tumour. 
Up to now, 131-I-MIBG alone has mostly been used in patients
resistant to conventional therapy with a partial remission achieved
in more than 30% of cases (Mastrangelo, 1987; Matthay et al,
1998). The only significant toxicity was myelosuppression. Thus,
131-I-MIBG shows a response rate in NB similar to, if not better
than, the most active chemotherapeutic agents. Good results, 
with mild haematological toxicity, have also been obtained using
131-I-MIBG alone at diagnosis. (Mastrangelo et al, 1989;
Mastrangelo and Voute, 1991; Mastrangelo et al, 1993; Dekraker et
al, 1995).
The final objective of the work we have underway is to develop
a regimen for advanced NB to be adopted at diagnosis, based on
the simultaneous use of all available drugs, known to be effective
against NB, in combination with 131-I-MIBG. In the present study
response rates, and principally, ways of overcoming potential tox-
icity of CO-TH have been investigated. We have studied this novel
therapeutic approach first in resistant NB patients and then in a
number of cases with advanced disease at diagnosis. 
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Summary Biological and clinical observations suggest that initial marked reduction of resistant clones may be critical in any attempt to
improve long-term results in advanced neuroblastoma (NB). The aim of this pilot study is to determine short-term toxicity and efficacy of a new
therapeutic model based on the simultaneous use of multiple drug chemotherapy and specific irradiation using 131-I-MIBG. The study
population consisted of 21 patients, from 1 to 8 years of age with good 131-I-MIBG uptake. 16 extensively pre-treated patients with refractory
or relapsed disease were divided into 2 groups. In Group 1 (9 patients) the basic chemotherapy regimen consisted in cisplatin at the dose of
20 mg/m2 i.v. per day infused over 2 h, for 4 consecutive days; on day 4 Cy 2 g/m2 i.v. was administered over 2 h followed by Mesna. Group
2 (7 patients) was treated with basic chemotherapeutic regimen plus VP16 and Vincristine. VP16 at the dose of 50 mg/m2 i.v. per day was
administered as a 24 h infusion on days 1–3; Vincristine 1.5 mg/m2 i.v. was administered on days 1 and 6. On day 10 a single dose of 131-I-
MIBG (200 mCi) with a high specific activity (>1.1 GBq/mg) was administered to both Groups by i.v. infusion over 4–6 hours. A further 5
patients were treated at diagnosis: 2 with the same regimen as Group 1 and 3 with the same as Group 2. The severity of toxicity was graded
according to World Health Organization (WHO) criteria. Assessment of tumour response was monitored 4–6 weeks after the beginning of
combined therapy (CO-TH). Response was defined according to INSS (International Neuroblastoma Staging System) criteria. No extra-
medullary toxicity was observed in any patient. Haematological toxicity was the only toxicity observed and seemed mainly related to
chemotherapy. Myelosuppression was mild in the 5 patients treated at diagnosis. No serious infections or significant bleeding problems were
observed. In the 16 resistant patients, 12 PR, 1 mixed response and 3 SD were obtained. In the 5 patients treated at diagnosis 2 PR, 1 CR
and 2 VGPR were observed. No alteration in 131-I-MIBG uptake was observed after the chemotherapy preceding radio-metabolic treatment.
The therapeutic results of this pilot regimen of CO-TH resulted in a high percentage of major response after only a single course in both
resistant patients and patients treated at diagnosis. Because of the minimal toxicity observed in patients studied at diagnosis so far, there is
room for gradual intensification of the treatment. It is to be hoped that this suggested novel approach may represent an important route of
investigation to improve final outcome in patients with advanced NB. © 2001 Cancer Research Campaign http://www.bjcancer.com
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PATIENTS AND METHODS 
From 1996 to date, 21 patients ³1 year of age with advanced NB,
underwent CO-TH. 16 with refractory or relapsed disease and 5
patients with advanced disease at diagnosis were admitted to the
study. Informed parental consent was obtained in all cases. 
16 patients (11 males, 5 females), aged 1 to 8 years (median 5
years), with relapsed or refractory NB were treated. All patients
showed evaluable disease and a good 131-I-MIBG uptake at enrol-
ment. The median interval between the last day of prior treatment
and the beginning of CO-TH was 3 months (range 1–12 months);
most patients were treated following recovery from previous tox-
icity. All were heavily pre-treated with multiple courses of
combined agents including platinum compounds, cyclophos-
phamide (Cy), VP-16 and Vincristine (VCR). Group 1 included 9
patients treated with a regimen based on cisplatin and Cy adminis-
tered before 131-I-MIBG. Subsequently, in the second group of 7
patients (Group 2) VP16 and VCR were included in the
chemotherapy regimen. Patients in both groups were comparable
in regard to intensity of prior treatment. 
5 patients with newly diagnosed advanced NB with a good 131-
I-MIBG uptake were treated with CO-TH. There were 4 males and
1 female, ranging in age from 2 to 4 years; 4 presented with Stage 4
disease and one with a non-resectable Stage 3 NB. In patients 2 and
5, bone marrow was heavily infiltrated by neuroblastoma cells. 
Evaluation 
Method for assessment of disease extent just before and following
CO-TH included: computerised tomography (CT) or nuclear
magnetic resonance (NMR) imaging of tumour mass and 131-I-
MIBG or 123-I-MIBG scan; technetium-99 m scan and/or X-rays
were also used for evaluation of bone disease. Bone marrow aspira-
tion from four different sites on the iliac crest and biopsy specimens
from two sites completed the evaluation. 24 urine collections were
carried out for catecholamines and catecholamine metabolites.
Cardiac and kidney functions were also investigated and audio-
grams were performed, prior to and following CO-TH; evaluation
of toxicity was scheduled, including ECG and echocardiography
for cardiac function; renal function was assessed by 24 h creatinine
clearance and sequential renal angioscintigraphy. Haematological
toxicity was assessed by performing complete blood cell counts
2–3 times a week. Severity of toxicity was graded according to
World Health Organization criteria (WHO, 1979). Assessment of
tumour response was monitored 4 to 6 weeks after the beginning of
CO-TH. Response was defined according to INSS criteria (Brodeur
et al, 1993). Semi-quantitative measurement of 131-I-MIBG
uptake was carried out on planar images by calculating tumour-
to-background ratios using the region of interest (ROI) analysis.
Radionuclide uptake was expressed in the ratio of average counts
of pixels in the tumour ROI to average counts of pixels in back-
ground ROI (drawn in a region adjacent to the tumour). 
Treatment regimen 
An outline of the final CO-TH regimen is shown in Figure 1. The
basic chemotherapy regimen (Group 1) consisted in cisplatin at the
dose of 20 mg/m2 per day given as a 2 h i.v. infusion for 4 conse-
cutive days; on day 4 cyclophosphamide (Cy) 2 g/m2 i.v. was
administered over 2 h followed by Mesna. In patients from Group
2, VP16 and VCR were also included (regimen 2). VP16 at the
dose of 50 mg/m2 i.v. per day was given as a 24 h infusion on days
1–3; vincristine, 1.5 mg/m2 i.v., was administered on days 1 and 6.
On day 10 a single dose of 131-I-MIBG (200 mCi) with a high
specific activity (>1.1 GBq/mg) was given by i.v. infusion over
4–6 hours. A reduced dose of 100 mCi was planned for children
under 2 years of age. Radiation dosimetry was not performed.
Iodine solution for thyroid blocking was commenced 3 days
before 131-I-MIBG infusion and continued for 3 weeks. Post-
therapeutic 131-I-MIBG imaging was recorded weekly. 
The first 2 patients treated at diagnosis received CO-TH
regimen 1; the last 3 patients received regimen 2
RESULTS 
Toxicity 
The 21 patients submitted to CO-TH did not show any acute side-
effects directly related to 131-I-MIBG administration apart from
occasional vomiting and a single episode of mild acute haemor-
rhagic cystitis. No extra-medullary toxicity was observed from the
beginning of treatment and during the study period. Specifically,
no changes were detectable in renal or cardiac function; on the
whole, the general condition of these children has been excellent. 
In the resistant patients of Groups 1 and 2, a comparable haem-
atological toxicity was observed. In most patients, a nadir in the
absolute neutrophil count (ANC) of below 500/mm3 occurred
between day 6 and day 20 with a duration of 3–15 days; a nadir in
the platelet (PLT) count of below 50 000 occurred on approx-
imately day 15 and lasted 2–5 days. In patients who had received
melphalan at standard dosage within 2 months prior to CO-TH, a
prolonged neutropenia and thrombocytopenia were observed.
However, no serious infections or bleeding tendencies were
observed in any of the patients investigated. Figure 2 shows in
detail the time course of neutrophil and platelet mean values in
patients of Groups 1 and 2 combined. 
In the 5 patients treated at diagnosis, myelosuppression was
relatively mild and appeared to be related solely to the effect of the
chemotherapeutic agents. Despite ANC even of below 500/mm3 at
the time of 131-I-MIBG administration, recovery from myelosup-
pression was rapid in cases 1, 3 and 4 (range 7–10 days). In cases
2 and 5, where there was massive BM infiltration, haematological
recovery was somewhat less rapid, since ANC and platelet counts
were respectively >2000 and >150 000 mm3 3 weeks after 
131-I-MIBG administration. Although these are preliminary data,
haematological toxicity from subsequent courses of chemotherapy
appears comparable to that experienced by patients with advanced
Cisplatin 20 mg/sqm i.v.
VP 16 50 mg/sqm c.i.
Cyclophoshamide 2 gr/sqm i.v.
Vincristine 1.5 mg/sqm i.v.
131-I-MIBG 200 mCi i.v.
1234567891 0 Days
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NB treated in our centre with identical drug combinations but
without prior CO-TH. 
Clinical response 
The overall response rate in Groups 1 and 2 combined shows 12
PR (75%), I mixed response and 3 SDs (see Tables 1 and 2). The
median duration of progression-free survival from the beginning
of CO-TH was 12 months (range 3–42 months). 3 patients are in
continuous complete remission: patient 5 (Table 1) and patient 15
(Table 2) are in continuous CR respectively at 35 and 28 months
following surgery, patient 7 (Table 1) following surgery and BMT
at 42 months. The high response rate was observed even in patients
who appeared to be previously resistant to drugs used in CO-TH. 
Clinical response, evaluated 4–5 weeks following the beginning
of CO-TH, of patients treated at diagnosis, included 2 PR 1 CR
and 2 VGPR (see Table 3). In particular, the CT scan of case 3
showed, 5 weeks from start of treatment, an almost 100% reduc-
tion of the primary tumour, while the 131-I-MIBG scan was
completely negative. BM and catecholamines were normal. 
Results of semi-quantitative measurement of 131-I-MIBG
uptake are shown in Table 4. No evidence of modified uptake was
observed in the 6 patients (four at diagnosis) investigated before
and after treatment with 2- and 4-drug chemotherapy, just before
131-I-MIBG administration. 
DISCUSSION 
Current treatment of advanced neuroblastoma (NB) has so far
produced a poor prognosis. Results of even intensive chemotherapy
are disappointing as compared to other childhood malignant
tumours. In advanced NB, as with ALL and B lymphoma, it may be
essential to increase the proportion of patients achieving a CR in a
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Figure 2 Time course of absolute neutrophil (ANC ´ 109/I) (a) and platelet
counts (PLT ´ 109/I) (b) following CO-TH (*data over line). Individual and
mean values are shown. The arrow indicates days of 131-I-MIBG
administration.
Table 1 Patients’ characteristics and results of treatment in Group 1 resistant NB
Pt. Sex/Age Disease extent Previous treatment Disease status Response
Soft tissues BM Boney lesions
1 M/2 Abdominal mass 30% Humerus De CECAT (4) 2nd relapse PR
mediastinic mass HDCY-Adr (4) PD
Cis-131-I-MIBG (2)
2 F/6 Cerebral – – De CECAT (6) 1st relapse PR
localization ABMT (Bu-CP16-Thio)
3 M/3 Abdominal mass – – PTC (2) De CECAT (4) 1st relapse PR
Hepatic lesions HDCY-Adr (2) PD
ABMT (Bu-CY-Melph)
4 M/3 Abdominal mass 10% Pelvis 131-I-MIBG (2) 1st relapse PR
Femur CaDO (2) PD
Rib Carbo-VP16 (2)
5 F/3 Adrenal mass – – De CECAT (4) Refractory SD
6 M/3 – 30% Femur De CECAT (3) Refractory Mixed
Cnemis HDCY-Adr (2) Response
Melph (2)
7 M/5 Adrenal mass 4% Pelvis De CECAT (4) Refractory PR
HDCY-Adr (2)
Melph (1)
8 M/8 Mediastinic mass – – De CECAT (4) Refractory PR
ABMT (Bu-VP16-Thio)
Melph (3)
9 F/5 Adrenal mass – 1st throracic vertebra De CECAT (4) Refractory SD
Rib HDCY-Adr (2)short time. Long-term survivors are rare in advanced NB, and they
are almost invariably patients in whom a CR has been rapidly
obtained (Simone, 1984). A higher percentage of long-term
survivors may also depend on a better quality of first remission,
since recurrence, for the present, is frequent. 
The present study describes a new combination therapy (CO-
TH) in advanced NB, which uses, in resistant patients as well as in
patients at diagnosis, all non-cross-resistant drugs efficacious in
this disease, to be administered shortly before 131-I-MIBG. This
radio-active drug is known to be effective in NB-resistant patients.
For our heavily pretreated patients, the therapeutic results seem to
be very encouraging in terms of degree and rapidity of response
after only a single course of multiple drug chemotherapy in
combination with 131-I-MIBG. In similar patients treated with
intensive chemotherapy or 131-I-MIBG alone, therapeutic results
are less impressive and usually obtained after a number of treat-
ment courses administered over several months (Philip et al, 1987;
Pinkenton et al, 1990; Frappaz et al, 1992; Dekraker et al, 1995).
Our results may be partly due to the potential synergism between
cisplatin, included in the CO-TH, which is apparently still present
in tumour tissue for long periods after its administration, and radi-
ation from 131-I-MIBG administration. 
Due to the inaccuracies of dosimetric calculations in advanced
NB (Beierwaltes, 1987), neither tumour nor whole-body radiation
dosimetry was attempted. Instead, we administered a substantial
single dose of 131-I-MIBG – approximately 200 mCi – using a
similar dose in all the patients studied. This 131-I-MIBG dose was
chosen because it is considered to be effective in NB and appar-
ently safe when administered alone (Dekraker et al, 1995). 
Tumour dose absorption may theoretically have been reduced in
our cases as a consequence of chemotherapy, possibly because of a
131-I-MIBG and multidrug therapy in advanced neuroblastoma 463
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Table 2 Patients’ characteristics and results of treatment in Group 2 resistant NB
Pt. Sex/Age Disease extent Previous treatment Disease status Response
Soft tissue BM Bony lesion
10 F/7 Cerebral 90% Lumbar rachis De CECAT (4) 2nd relapse PR
Localization Rib ABMT (Bu-VP16-Thio) PD
Pelvis 131-I-MIBG (2)
11 M/4 Adrenal mass – Lumbar De CECAT (6) Refractory PR
Mediastinic mass rachis HDCY-Adr (2)
12 M/3 Adrenal 3% – De CECAT (4) Refractory SD
Mediastinal mass HDCY-VP16 (2)
13 M/1 Mediastinic mass – – CY-VP16 (2) Refractory PR
CY-Adr (1)
Cis-131-I-MIBG (1)
14 M/6 Adrenal mass – – CY-Adr (2) Refractory PR
Hepatic mass Carbo–VP16 (2)
Thoracic lesions CY-CP16 (1)
ABMT (CARBO-VP16-Thio-Melph)
15 M/2 Adrenal mass – – IFO-Adr (2) Refractory PR
CY-VP16 (2)
HDCY 2)
16 F/1 Abdominal mass – – CARBO-VP16 (2) 1st relapse PR
IFO-Adr (2)
CY-VP16 (2)
ABMT (Thio-Melph)
(CY-Thio)
(Melph)
Table 3 Patients’ characteristics and results of treatment in advanced NB at diagnosis
Pt. Sex/Age Disease extent Regimen Response (after 4–5 weeks)
Soft tissue BM Cortical bony Combined therapy
lesions (single course)
1 M/3 +++ + +++ Cis-Cy---131-I-MIBG PR
2 F/3 +++ +++ +++ Cis-Cy---131-I-MIBG PR
3 M/2 +++ ++ +++ Cis-Cy-VP16-VCR-131-I-MIBG CR
4^ M/4 +++ – – Cis-Cy-VP16-VCR-131-I-MIBG VGPR
5 M/3 ++ +++ ++ Cis-Cy-VP16-VCR-131-I-MIBG VGPR
^3rd stage
Table 4 Tumor (T)/Background (B) 131-I-MIBG uptake ratio before and
after chemotherapy
T/B at 24 h T/B at 48 h
Pre Post Pre Post
Case n. 10R 1,35 1,5 1,5 1,9
Case n. 1 2,4 2,7 3,6 3,5
Case n. 2 2,1 2,7 2,15 2,9
Case n. 4 4,8 4,8 7,0 7,1
Case n. 5 1,95 1,98 – – 
Case n. 16R 1,66 1,66 – –464 S Mastrangelo et al 
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less active 131-I-MIBG uptake secondary to a decreased number of
metabolically competent tumour cells. However, observations both
‘in vitro’ and ‘in vivo’ in xenograft models (Meco et al, 1997;
Riccardi, unpublished observations) and in 6 of our patients, showed
no evident alteration in MIBG uptake (Table 4). In fact, it is worth
noting that NB cells, pre-incubated with cisplatin, concentrate MIBG
more efficiently than untreated NB cells (Armour et al, 1997).
Our primary concern was haematological and non-haematolog-
ical toxicity as a result of this new therapeutic regimen. In our
previous work with a different CO-TH regimen a prolonged haema-
tological toxicity was observed (Mastrangelo et al, 1995;
Mastrangelo et al, 1997). In the present investigation the rationale
for the drugs plus 131-I-MIBG sequence rests on experimental
work in a murine model. Whereas, in mice, Cy administered after
total body irradiation (TBI) is associated with severe haematolog-
ical toxicity, it was found that pre-treatment with Cy significantly
reduced TBI-induced mortality, perhaps by enhancement of BM
recovery rather than by stem cell protection (Millar and Hudspith,
1976; Yan et al, 1991). Tumour tissue is not protected by Cy pre-
treatment. Subsequently, pretreatment with other drugs such as
ARA-C and Vinblastine, in addition to Cy, appeared to protect mice
from an otherwise lethal dose of radiation, suggesting that a
common biological mechanism may be involved, such as rapid
myeloid cell destruction (Millar et al, 1971). The optimum interval
between administration of these drugs and radiation is 2–3 days, but
we empirically chose a longer interval between chemotherapy and
131-I-MIBG administration, in consideration of different human
haematopoiesis. CO-TH was well tolerated with this regimen. Our
resistant, heavily pre-treated patients showed an acceptable haema-
tological toxicity. A severe haematological toxicity was observed in
3 cases, possibly because melphalan, a drug which specifically
causes stem cell damage, had been administered in a previous ther-
apeutic regimen about 4–6 weeks before CO-TH. When a nadir for
platelets and neutrophils might be expected from 131-I-MIBG, i.e.
during the 4th and 5th weeks (Lashford et al, 1992), there was
already a trend toward haematological recovery in the majority of
patients studied. It is therefore suggested that the limited haemato-
logical toxicity observed was due to a ‘priming effect’ of the
chemotherapy even though many patients did not have bone
marrow involvement. It is interesting to note that there was no
extra-haematological toxicity in any of the patients. 
On the basis of these encouraging results and, above all, the
acceptable haematological toxicity in resistant patients, we feel
that CO-TH could be a promising therapeutic approach to use at
the time of diagnosis. 
Although they are preliminary, the results of CO-TH therapy in the
5 patients with advanced NB treated at diagnosis suggest that this
regimen is very efficacious even after a single course of treatment. 
In conclusion, while this is an ongoing study it already demon-
strates that our innovative CO-TH therapy is feasible and most
effective in obtaining a rapid response in heavily pre-treated resist-
ant patients and in patients treated at diagnosis. In the latter,
considering that only mild haematological toxicity occurred, a
carefully monitored dose-escalation of CO-TH could be contem-
plated with the aim of rapidly eradicating the maximum number of
tumour cells before resistance is acquired. 
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